Molecular Basis and Advances of Targeted Therapy for Breast Cancer: Second Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 March 2025 | Viewed by 50
Special Issue Editors
Interests: cancer; resistance to TK or CDK inhibitors; epigenetics; NGSseq
Special Issues, Collections and Topics in MDPI journals
Interests: high mobility group A (HMGA) proteins; chromatin; regulation of gene expression; protein–protein interactions; post-translational modifications (PTMs); epithelial–mesenchymal transition; proteomics; tumor microenvironment; breast cancer; metastasis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue focuses on translational science in the hopes of shedding light on research focused on “Molecular Basis and Advances of Targeted Therapy for Breast Cancer” and the therapy on breast cancer and overcoming breast cancer therapy resistance. Breast cancer (BC) is the most frequent cancer and the second cause of death by cancer in women worldwide.
The BC molecular subtype can determine the personalized therapeutic approach, e.g., targeted treatments such as endocrine therapy for HR+ BC or anti-HER2 therapy for HER2+ BC. The major challenge in BC treatment is finding active therapies to treat triple-negative breast cancer (TNBC) patients since conventional targeted therapies cannot be administered for this specific BC subtype, which has the worst survival outcomes. the mechanisms underlying drug resistance are a good strategy to develop novel treatments for BC. Acquired drug resistance is one of the main restrictions to the efficacious treatment of cancer. The mTOR/PI3K/Akt pathway is involved in the mechanism of resistance in all BC molecular subtypes, but many data show that resistance results from drug exclusion, drug metabolism, and modification of the drug target due to mutation or overexpression. Depending on the therapy, one or more genetic or epigenetic modulations are required to confer resistance to treatment. The editors welcome submissions from researchers involved in basic cancer research as well as clinical research. The articles should demonstrate a clear understanding of tumor cells and treatment strategies specific to the tumor types and clarify the ways that lead to therapy resistance from cell lines to clinical trials. Reviews and original papers are both welcome.
Dr. Nicoletta Cordani
Prof. Dr. Manfioletti Guidalberto
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- targeted therapy
- cancer therapy
- resistance
- epigenetic modulations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
